

Recombinant Rat Interleukin–1 β (r IL-1 β)

PRODUCT ANALYSIS SHEET

Catalog Number:	PRC0811
Lot Number:	L121802
Quantity:	100 µg
Molecular Weight:	17.3 kDa (152 amino acid residues)
Purity:	>95% as determined by SDS-PAGE analysis.
Biological Activity:	ED_{50} range = 0.2-0.5 ng/mL, determined by the dose dependent proliferation of mouse D10S cells. Optimal concentration for individual application should be determined by a dose response assay.
Formulation:	Lyophilized, carrier-free
Sterility:	Filtered prior to lyophilization through a 0.22 micron sterile filter.
Endotoxin:	<0.1 ng/µg
Production:	Produced in E. coli and purified by sequential chromatography.
Reconstitution Recommendation:	We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute lyophilized rIL-1 β in sterile, distilled water to a concentration of 0.1-1.0 mg/mL. Recombinant rIL-1 β is also soluble in most buffered solutions. Further dilutions should be made in buffered solution containing a carrier protein such as PBS + 0.1% BSA.
Suggested Working Dilutions:	The optimal concentration should be determined for each specific application.
Storage:	Store lyophilized rIL-1 β at 2-8°C, preferably desiccated. Upon reconstitution, apportion into working aliquots and store at \leq -20°C. Avoid repeated freeze/thaw cycles.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PRC0811

(Rev 1.0) (DCC-08-1232) Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, www.invitrogen.com). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.



References: Hou, S.H., H.C. Guan, and R.P. Ricciardi (2002) In adenovirus type 12 tumorigenic cells, major histocompatibility complex class I transcription shutoff is overcome by induction of NF-kappa B and relief of COUP-TFII repression. J. Virol. 76(7):3212-3220.

Orencole, S. F. and C. A. Dinarello (1989) Characterization of a subclone (D10S) of the D10.G4.1 helper T-cell line which proliferates to attomolar concentrations of interleukin-1 in the absence of mitogens. Cytokine 1:14-22.

Nagy, Z., J. Radeff, and P.H. Stern (2001) Stimulation of interleukin-6 promoter by parathyroid hormone, tumor necrosis factor alpha, and interleukin-1 beta in UMR-106 osteoblastic cells is inhibited by protein kinase C antagonists. J. Bone Mineral Research 16(7):1220-1227.

Nguyen, K.T., T. Deak, S. M. Owens, T. Kohno, M. Fleshner, L.R. Watkins, and S.F. Maier (1998) Exposure to acute stress induces brain interleukin-1 β protein in the rat. The Journal of Neuroscience 18(6):2239-2246.

Radeff, J., Z. Nagy, and P.H. Stern (2001) Involvement of PKC-ß in PTH, TNF-a and IL-1b effects on IL-6 promoter in osteoblastic cells and on PTH-stimulated bone resorption Experimental Cell Research 268:179-188.

This product is for research use only. Not for use in diagnostic procedures.

www.invitrogen.com

Manufactured under ISO 13485 Quality Standard

Invitrogen Corporation • 542 Flynn Rd • Camarillo • CA 93012 • Tel: 800.955.6288 • E-mail: techsupport@invitrogen.com

PI PRC0811

Important Licensing Information - These products may be covered by one or more Limited Use Label Licenses (see the Invitrogen Catalog or our website, <u>www.invitrogen.com</u>). By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.



(Rev 1.0) (DCC-08-1232)